- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07930260
Efficacy and Safety of Kabalin Cap.(Pregabalin) in Patients With Neuropathic Pain
A Multi-center, Prospective, Observational Study to Evaluate Therapeutic Effectiveness and Safety of Kabalin Cap. in Patients With Neuropathic Pain
This study aims to assess the proportion of patients with peripheral or central neuropathic pain who achieve at least a 50% improvement in pain at Week 12 after receiving Kabalin Cap.(Pregabalin). The study will also evaluate changes in pain characteristics, severity, and intensity; improvement in pain-related sleep interference; and safety information collected during the study period.
Study Overview
Status
Conditions
Detailed Description
This study will evaluate pain-related outcomes and safety in patients with peripheral or central neuropathic pain who receive Kabalin Cap.(Pregabalin). At Week 12 after treatment initiation, the proportion of patients who achieve at least a 50% improvement in pain will be assessed. Changes in pain characteristics, severity, and intensity will also be evaluated. In addition, the study will assess improvement in pain-related sleep interference and collect safety information observed during the study period.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Yong-an Jeong
- Phone Number: +82-31-5176-4673
- Email: yongan.jeong@inno-n.com
Study Contact Backup
- Name: Seung kye Cho
- Phone Number: +82-31-5176-4676
- Email: seungkye.cho@inno-n.com
Study Locations
-
-
-
Seoul, South Korea
- Recruiting
- HK inno.N
-
Contact:
- Seung Kye Cho
- Phone Number: +82-31-5176-4676
- Email: seungkye.cho@inno-n.com
-
Contact:
- Ahrong Kim
- Phone Number: +82-31-5176-4666
- Email: ahrong.kim@inno-n.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
University-affiliated hospitals and general hospitals where the study drug is administered
Description
Inclusion Criteria:
- Aged 19 years or older
- Patients for whom treatment with Kabalin Cap. has been selected in accordance with the approved prescribing information for peripheral or central neuropathic pain
- Patients who voluntarily provide written informed consent
- Patients who are able to complete the questionnaires
Exclusion Criteria:
- Patients with hypersensitivity to pregabalin or any of the excipients
- Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- Pregnant or breastfeeding women
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_ONLY
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of participants with a ≥50% improvement in pain severity from baseline at Week 12
Time Frame: At Week 12 after enrollment
|
The proportion of participants whose pain severity score, as assessed using the SF-MPQ, shows a ≥50% improvement from baseline after 12 weeks of treatment with Kabalin Cap. will be reported |
At Week 12 after enrollment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IN_PGL_N01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.